Barclays Trims Moderna (NASDAQ:MRNA) Target Price to $125.00

Moderna (NASDAQ:MRNA) had its target price cut by Barclays from $155.00 to $125.00 in a report issued on Monday morning, Benzinga reports. They currently have an overweight rating on the stock.

MRNA has been the subject of a number of other reports. Jefferies Financial Group lowered shares of Moderna from a buy rating to a hold rating and reduced their price target for the company from $120.00 to $65.00 in a research report on Friday, September 13th. Royal Bank of Canada dropped their price objective on shares of Moderna from $90.00 to $75.00 and set a sector perform rating for the company in a report on Friday, September 13th. William Blair reaffirmed a market perform rating on shares of Moderna in a report on Thursday, June 27th. TD Cowen dropped their price objective on shares of Moderna from $70.00 to $60.00 and set a hold rating for the company in a report on Friday, September 13th. Finally, Bank of America dropped their price objective on shares of Moderna from $130.00 to $110.00 and set a neutral rating for the company in a report on Friday, September 13th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of Hold and an average price target of $100.44.

Moderna Stock Down 3.0 %

MRNA opened at $69.86 on Monday. The company has a fifty day moving average price of $92.28 and a 200-day moving average price of $111.27. The firm has a market capitalization of $26.77 billion, a P/E ratio of -4.46 and a beta of 1.68. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92. Moderna has a one year low of $62.55 and a one year high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. The firm had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business’s revenue for the quarter was down 29.9% on a year-over-year basis. During the same period in the previous year, the business earned ($3.62) EPS. Equities research analysts expect that Moderna will post -9.52 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO James M. Mock sold 689 shares of the company’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $118.24, for a total transaction of $81,467.36. Following the completion of the transaction, the chief financial officer now directly owns 7,269 shares of the company’s stock, valued at $859,486.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $127.22, for a total transaction of $1,908,300.00. Following the completion of the transaction, the director now directly owns 2,284,015 shares of the company’s stock, valued at $290,572,388.30. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO James M. Mock sold 689 shares of the company’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $118.24, for a total transaction of $81,467.36. Following the transaction, the chief financial officer now directly owns 7,269 shares of the company’s stock, valued at $859,486.56. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 93,158 shares of company stock valued at $11,167,312. Insiders own 15.70% of the company’s stock.

Hedge Funds Weigh In On Moderna

Several hedge funds and other institutional investors have recently modified their holdings of MRNA. Quadrant Capital Group LLC increased its position in shares of Moderna by 7.5% during the fourth quarter. Quadrant Capital Group LLC now owns 2,672 shares of the company’s stock valued at $266,000 after buying an additional 187 shares during the period. Kentucky Retirement Systems increased its position in shares of Moderna by 3.3% during the fourth quarter. Kentucky Retirement Systems now owns 26,541 shares of the company’s stock valued at $2,640,000 after buying an additional 852 shares during the period. Norges Bank purchased a new position in shares of Moderna during the fourth quarter valued at about $347,565,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Moderna during the fourth quarter valued at about $200,000. Finally, Sachetta LLC purchased a new position in shares of Moderna during the fourth quarter valued at about $56,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.